47 results about "Inflammatory molecules" patented technology

The present invention provides supramolecular hydrogels having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof. Applications of the present invention include use of the supramolecular hydrogel, for instance, as a biomaterial for wound healing, tissue engineering, drug delivery, and drug / inhibitor screening.

Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

The present invention pertains to the design and application of a supramolecular hydrogel having a three-dimensional, selfassembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof. The design of the hydrogel includes: 1) modifying functional molecules to convert them into hydrogelators while enhancing or maintaining their therapeutic properties and 2) triggering -the hydrogelation process by physical, chemical, or enzymatic processes, thereby resulting in the creation of a supramolecular hydrogel via formation of non-covalent crosslinks by the functional molecules. Applications of the present invention include use of the supramolecular hydrogel, for instance, as a biomaterial for wound healing, tissue engineering, drug delivery, and drug / inhibitor screening.

Methods and compositions are disclosed for reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

A method and composition for treating in a mammalian subject a condition accompanied or caused by IgE mediated histamine release from mast cells comprising administering to a subject in need of such treatment a therapeutically effective amount of the pharmaceutical composition an amylase peptide or derivative thereof.

Diagnostic screening tests that can be used to identify if a patient is a good candidates for an implantable vagus nerve stimulation device. One or more analyte, such as a cytokine or inflammatory molecule, can be measured from a blood sample taken prior to implantation of a vagus nerve stimulator to determine the patient's responsiveness to VNS for treatment of an inflammatory disorder.

Stimulation of neural signalling of an apical splenic nerve can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders.

Methods and compositions are disclosed for reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

The invention relates to a Kirenol derivative and an application thereof in preparation of a proinflammatory cytokine inhibitor. The Kirenol derivative shown in a general formula (I) and a general formula (II) can inhibit the proinflammatory cytokine tumor necrosis factor (TNF)-alpha, the interleukin (IL)-1beta and the inflammatory molecule nitrogen oxide and is suitable for drug preparation.

The invention relates to a preparation method and application of tolerogenic dendritic cells capable of keeping stability in the inflammatory environment. The preparation method is characterized by using a monomer structure compound for carrying out targeted inhibition on phosphorylation of mTOR signal channel protein, and carrying out in-vitro tolerance short-time induction and culture of human dendritic cells. The result shows that the prepared tDC still maintains a stable tolerance regulation function when the tDC is irritated by inflammatory molecules. A new tDC preparation method is builtand is capable of ensuring the survival rate of cell products in moderate concentration and time and preparing tDC cell products which can still stably maintain the tolerance function in the inflammatory environment; the raw materials adopted by the preparation method easily pass GMP authentication; the preparation process is simple, convenient and economical; the prepared products are stable andeffective and are easily standardized; the prepared tDC can be applied to adoptive infusion, can be used for treating multiple allergic immune reactive diseases, and has great potential in clinical application.

Methods and reagents for screening for anti-microbial agents are provided. Diagnostic tools for assessing treatment of fungal infections are provided. Antimicrobial substances including substances useful for the treatment of fungal infections are provided. In some embodiments, the substances have antigen unmasking activity. In some embodiments the substances have fungicidal activity and surface antigen unmasking activity.

The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as Lactobacillus rhamnosus, and methods for using such bioactive molecules to activate NOD2, decrease expression of inflammatory molecules, inhibit replication of human immunodeficiency virus (HIV), stimulate expression of Apolipoprotein A-IV, modulate diet-associated weight gain and prevent mucosal transmission of HIV.

The present invention relates to biofunctional polymeric substrates product comprising immobilized antibodies that selective bind to antigens namely autologous growth factors and an inflammatory molecule, uses and method of production. The bio-functional polymeric substrate can be used in a quantification method of antigens namely soluble growth factors, inflammatory molecules and hormones or the biofunctional polymeric substrate can be used to isolate extracellular vesicules. The biofunctional polymeric substrate can be also used in Tissue Engineering and Regenerative Medicine approaches, namely in bone and cartilage lesions, esophageal lesions, periodontal ligament reconstruction and skin lesions regeneration or treatment.

Disclosed herein is a method for treating an inflammatory disease in a subject, including administering to the subject a therapeutically effective amount of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter. Also disclosed is a method for reducing the expression of a pro-inflammatory molecule in a cultured cell, including contacting the cultured cell with the saidDHLA coated gold nanocluster. Still disclosed is a pharmaceutical composition that includes the present DHLA coated gold nanocluster. The pharmaceutical composition is useful for treating the inflammatory disease in the subject.

Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and / or diabetic inflammation.

Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is adjacent to the splenic artery at a position where the splenic artery is not in direct contact with the pancreas, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating disorders, such as disorders associated with inflammation. The invention provides improved ways of reducing inflammation with minimized off-target effects, in particular surgical trauma.

Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

The present invention relates to a new process for identifying novel anti-inflammatory molecules with reduced direct transrepression of genes induced by glucocorticoids.The inventors have discovered that GCs-mediated transrepression can be mediated not only via the tethering indirect pathway, but also through direct binding of GR to “simple” negative GREs (nGRE), which belongs to a novel family of evolutionary-conserved cis-acting negative response elements (IR nGREs), and are found in numerous GC-repressed genes.

Augmented or synergized anti-inflammatory constructs are disclosed including anti-inflammatory amino acids covalently conjugated with other anti-inflammatory molecules such as nonsteroidal anti-inflammatory drugs, vanilloids and ketone bodies. Further conjugation with a choline bioisostere or an additional anti-inflammatory moiety further augments the anti-inflammatory activity.

Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is associated with a neurovascular bundle, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders. The invention provides improved ways of treating inflammatory disorders which minimize off-target effects.

Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is adjacent to the splenic artery at a position where the splenic artery is not in direct contact with the pancreas, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating disorders, such as disorders associated with inflammation. The invention provides improved ways of reducing inflammation with minimized off-target effects, in particular surgical trauma.

A device for detecting a biomarker for inflammation in a respiratory system includes a sample collection and / or holding area to receive an exhaled breath condensate (EBC) sample obtained from a respiratory system; an electrode system coupled to the sample collection area, the electrode system including reduced graphene oxide (rGO); and circuitry coupled to the electrode system. The circuitry is configured to apply a voltage to the EBC sample in the sample collection area via the electrode system and to measure a current via the electrode system in response to the voltage applied, in order to determine a concentration of nitrite in the EBC sample based on the current measured. The concentration of nitrite is a biomarker for inflammation in the respiratory system.

The present invention relates to a method for decontaminating glucose polymers or the hydrolysates of the pro-inflammatory molecules thereof. Said method includes a) providing glucose polymers or the hydrolysates thereof, b) optionally, detecting or assaying the pro-inflammatory molecules in the glucose polymers or the hydrolysates thereof provided in Step a), and c) carrying out the following purifying steps: i. treatment using an enzymatic preparation having detergent properties and clarification properties; ii. treatment using a pharmaceutical-grade activated carbon with very high adsorption properties and “micropore” porosity; iii. optionally, treatment using a second activated carbon with “mesopore” porosity; iv. passing them over a macroporous adsorbent polymer resin having porosity greater than 100 Angstroms; and v. continuous ultrafiltration at 5 kDa.

The invention provides a new medical application of a chiral spiro indole-pyran pyrimidine base compound, particularly application of the compound in preparation of anti-inflammatory drugs. An in vitro cyclooxygenase (COX) activity inhibiting experiment, an experiment of inhibiting generation of an inflammatory molecule (nitric oxide) in primary mice macrophage and inhibition test on an ear swelling and paw edema model in mice, show that the chiral compound has an obvious anti-inflammatory effect and has extremely low gastrointestinal injury effect; therefore, the chiral compound, as an active ingredient, can be prepared into anti-inflammatory drugs in various dosage forms through pharmaceutically acceptable technologies and auxiliary materials, so that the chiral compound has an excellent medical application prospect.

Stimulation of neural activity in a splenic arterial nerve at a position where the splenic artery is not in direct contact with the pancreas, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating disorders, such as disorders associated with inflammation. The invention provides improved ways of reducing inflammation with minimized off-target effects, in particular surgical trauma.

The present invention relates to the field of biotechnology and provides monoclonal tri-specific binding molecules that specifically bind to human IL-17A, human IL-17F, and a human pro-inflammatory molecule (in particular, TNFα) with high affinity. The invention also relates to DNA constructs encoding said binding molecules, related expression vectors and methods of production, and methods of treatment using said binding molecules.